Rani Therapeutics

Historical price data

Rani Therapeutics' mission is to replace injectable biologics with convenient oral pills using its innovative RaniPill™ technology, which mechanically delivers drugs through the intestinal wall. The company has achieved key clinical milestones, demonstrating safety, tolerability, and bioavailability comparable to subcutaneous injections for its lead osteoporosis and ustekinumab biosimilar programs. Its strategy is to validate the platform through proprietary programs and subsequently pursue high-value partnerships with large biopharma companies to apply the technology to a broad range of biologic assets.

The RaniPill™ is an ingestible robotic capsule that autonomously performs a needle-less injection of a solid-state drug formulation into the intestinal wall, enabling the oral delivery of large-molecule biologics with bioavailability comparable to subcutaneous injection.

Faces competition from other oral delivery technologies (e.g., Oramed, Entera Bio), non-oral alternative delivery methods, and internal big pharma research. Rani's key differentiator is clinical data showing injection-like bioavailability via a unique mechanical delivery mechanism, avoiding the limitations of chemical enhancers.